2022
DOI: 10.1016/j.leukres.2022.106869
|View full text |Cite
|
Sign up to set email alerts
|

NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(5 citation statements)
references
References 19 publications
0
5
0
Order By: Relevance
“…We previously reported that STM were associated with inferior OS in a subset of NPM1+ AML patients, and thus suggested that STM could be useful in classification refinement. 7 STM were also reported to be associated with inferior OS among de novo normal karyotype AML patients, and HCT was reported to be a therapeutic strategy to overcome the adverse prognosis. 8 Wright et al found that STM+ NPM1+ AML was not associated with adverse OS and EFS among patients who received intensive chemotherapy.…”
Section: Table S2 Compares the Cytogenetic Abnormalities Between Pati...mentioning
confidence: 99%
“…We previously reported that STM were associated with inferior OS in a subset of NPM1+ AML patients, and thus suggested that STM could be useful in classification refinement. 7 STM were also reported to be associated with inferior OS among de novo normal karyotype AML patients, and HCT was reported to be a therapeutic strategy to overcome the adverse prognosis. 8 Wright et al found that STM+ NPM1+ AML was not associated with adverse OS and EFS among patients who received intensive chemotherapy.…”
Section: Table S2 Compares the Cytogenetic Abnormalities Between Pati...mentioning
confidence: 99%
“…Zhao et al [ 29 ] reported that TGFβ1 is a multifunctional cytokine involved in various biological processes, including cell growth, differentiation, apoptosis, and the immune response. TGFβ1 can inhibit leukemia cell proliferation by inhibiting cyclin synthesis and promoting apoptosis.…”
Section: Discussionmentioning
confidence: 99%
“…Another recent study provided preliminary evidence that NPM1-mut sAMLs are molecularly heterogeneous, with only a part of patients bearing sMut: patients with sMut exhibited a significant lower OS compared to those without sMut [82]. This property is not unique to NPM1-mut sAMLs but is also observed in NPM1-mut de novo AMLs [82].…”
Section: Npm1-mut Secondary Amlsmentioning
confidence: 95%